E.d. Bellis

After coming to market as a game changer the Johnson and Johnson vaccine which only requires one dose has been paused over blood clot concerns similar to their counterpart AstraZeneca. While this looks to be a temporary hiccup, this could slow the path towards herd immunity. Plus the top stories of the week and the top ten dangers of digital health.